Akero Therapeutics to Present at Upcoming Healthcare Conferences in November
11 November 2022 - 8:05AM
Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage
company developing transformational treatments for patients with
serious metabolic diseases marked by high unmet medical need, today
announced that management will present at the following investor
conferences this month:
- Jefferies London Healthcare Conference: Fireside chat on
Thursday, November 17 at 8:00 a.m. GMT (3:00 a.m. ET) in London,
England.
- EvercoreISI HealthCONx Conference: Fireside chat on Tuesday,
November 29 at 12:10 p.m. ET
Live webcasts of the Company presentations will be available
through the investor relations section of the Company's website
at www.akerotx.com. Following the live webcasts, archived
replays will be available on the Company's website.
About Akero TherapeuticsAkero Therapeutics is a
clinical-stage company developing transformational treatments for
patients with serious metabolic diseases marked by high unmet
medical need, including non-alcoholic steatohepatitis (NASH), a
disease without any approved therapies. Akero's lead product
candidate, efruxifermin (EFX), is a differentiated Fc-FGF21 fusion
protein that has been engineered to mimic the balanced biological
activity profile of native FGF21, an endogenous hormone that
alleviates cellular stress and regulates metabolism throughout the
body. EFX is designed to offer convenient once-weekly subcutaneous
dosing. The consistency and magnitude of observed effects position
EFX to be a potentially best-in-class medicine, if approved, for
treatment of NASH. EFX is currently being evaluated in two Phase 2b
clinical trials: the HARMONY study in patients with pre-cirrhotic
NASH (F2-F3 fibrosis), which is currently in a long-term safety
follow-up phase after reporting Week 24 results, and the SYMMETRY
study in patients with cirrhotic NASH (F4 fibrosis, compensated).
EFX is also being evaluated in an expansion cohort of the SYMMETRY
study, comparing the safety and tolerability of EFX to placebo when
added to an existing GLP-1 receptor agonist in patients with
pre-cirrhotic NASH (F1-F3 fibrosis) and Type 2 diabetes. Akero is
headquartered in South San Francisco. Visit us
at akerotx.com and follow us
on LinkedIn and Twitter for more
information.
Investor Contact:Christina TartagliaStern
Investor Relations,
Inc.212.362.1200christina.tartaglia@sternir.com
Media Contact:650.487.6488media@akerotx.com
Akero Therapeutics (NASDAQ:AKRO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Akero Therapeutics (NASDAQ:AKRO)
Historical Stock Chart
From Apr 2023 to Apr 2024